account_id none on file
legal_name Atrium Therapeutics, Inc.
ticker RNA
cik 2093101
domain aviditybiosciences.com
linkedin_company_url https://www.linkedin.com/company/avidity-biosciences-llc/
entry_point_account_id none on file
name Avidity Biosciences Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 7 executives 0 family 0
why_nownone on file
callsnone on file
filings
• Our headcount growth and associated costs as we expand our organization to achieve our objectives; • The costs of preparing, filing and prosecuting patent applications, and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and • The costs of operating as a public company.
filing / Aug 13, 2026 / receipt
Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products.
filing / Aug 13, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / Aug 13, 2026 / receipt
• Our headcount growth and associated costs as we expand our organization to achieve our objectives; • The costs of preparing, filing and prosecuting patent applications, and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and • The costs of operating as a public company.
filing / May 14, 2026 / receipt
Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products.
filing / May 14, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / May 14, 2026 / receipt
As a result of the post-pandemic continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who continue to work remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
filing / May 14, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug avidity-biosciences-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$